488 related articles for article (PubMed ID: 19105570)
1. Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells.
Yaqub S; Taskén K
Crit Rev Oncog; 2008; 14(1):57-77. PubMed ID: 19105570
[TBL] [Abstract][Full Text] [Related]
2. Regulatory T cells in immune surveillance and treatment of cancer.
Yamaguchi T; Sakaguchi S
Semin Cancer Biol; 2006 Apr; 16(2):115-23. PubMed ID: 16376102
[TBL] [Abstract][Full Text] [Related]
3. Beta2-adrenergic receptor signaling in CD4+ Foxp3+ regulatory T cells enhances their suppressive function in a PKA-dependent manner.
Guereschi MG; Araujo LP; Maricato JT; Takenaka MC; Nascimento VM; Vivanco BC; Reis VO; Keller AC; Brum PC; Basso AS
Eur J Immunol; 2013 Apr; 43(4):1001-12. PubMed ID: 23436577
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T-cells and cAMP suppress effector T-cells independently of PKA-CREM/ICER: a potential role for Epac.
Vang AG; Housley W; Dong H; Basole C; Ben-Sasson SZ; Kream BE; Epstein PM; Clark RB; Brocke S
Biochem J; 2013 Dec; 456(3):463-73. PubMed ID: 24007532
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue Y; Nishikawa H
Cancer Sci; 2019 Jul; 110(7):2080-2089. PubMed ID: 31102428
[TBL] [Abstract][Full Text] [Related]
6. Roles of regulatory T cells in cancer immunity.
Takeuchi Y; Nishikawa H
Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
[TBL] [Abstract][Full Text] [Related]
7. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T cells and innate immune regulation in tumor immunity.
Wang RF
Springer Semin Immunopathol; 2006 Aug; 28(1):17-23. PubMed ID: 16838179
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E
Li H; Chen HY; Liu WX; Jia XX; Zhang JG; Ma CL; Zhang XJ; Yu F; Cong B
Immunol Lett; 2017 Nov; 191():63-72. PubMed ID: 28963072
[TBL] [Abstract][Full Text] [Related]
10. CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects.
Kang SM; Tang Q; Bluestone JA
Am J Transplant; 2007 Jun; 7(6):1457-63. PubMed ID: 17511675
[TBL] [Abstract][Full Text] [Related]
11. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression.
Hiura T; Kagamu H; Miura S; Ishida A; Tanaka H; Tanaka J; Gejyo F; Yoshizawa H
J Immunol; 2005 Oct; 175(8):5058-66. PubMed ID: 16210609
[TBL] [Abstract][Full Text] [Related]
12. Interferon-α suppresses cAMP to disarm human regulatory T cells.
Bacher N; Raker V; Hofmann C; Graulich E; Schwenk M; Baumgrass R; Bopp T; Zechner U; Merten L; Becker C; Steinbrink K
Cancer Res; 2013 Sep; 73(18):5647-56. PubMed ID: 23878189
[TBL] [Abstract][Full Text] [Related]
13. Targeting regulatory T cells.
Ménétrier-Caux C; Curiel T; Faget J; Manuel M; Caux C; Zou W
Target Oncol; 2012 Mar; 7(1):15-28. PubMed ID: 22327882
[TBL] [Abstract][Full Text] [Related]
14. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer.
Sharma S; Yang SC; Zhu L; Reckamp K; Gardner B; Baratelli F; Huang M; Batra RK; Dubinett SM
Cancer Res; 2005 Jun; 65(12):5211-20. PubMed ID: 15958566
[TBL] [Abstract][Full Text] [Related]
15. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.
Pallandre JR; Brillard E; Créhange G; Radlovic A; Remy-Martin JP; Saas P; Rohrlich PS; Pivot X; Ling X; Tiberghien P; Borg C
J Immunol; 2007 Dec; 179(11):7593-604. PubMed ID: 18025205
[TBL] [Abstract][Full Text] [Related]
16. CD4+CD25+CD127 regulatory cells play multiple roles in maintaining HIV-1 p24 production in patients on long-term treatment: HIV-1 p24-producing cells and suppression of anti-HIV immunity.
Jiao YM; Liu CE; Luo LJ; Zhu WJ; Zhang T; Zhang LG; Su LS; Li HJ; Wu H
Int J Infect Dis; 2015 Aug; 37():42-9. PubMed ID: 26095899
[TBL] [Abstract][Full Text] [Related]
17. The suppressive effect of CD25+Treg cells on Th1 differentiation requires cell-cell contact partially via TGF-β production.
Shen E; Zhao K; Wu C; Yang B
Cell Biol Int; 2011 Jul; 35(7):705-12. PubMed ID: 21314640
[TBL] [Abstract][Full Text] [Related]
18. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2).
Czystowska M; Strauss L; Bergmann C; Szajnik M; Rabinowich H; Whiteside TL
J Mol Med (Berl); 2010 Jun; 88(6):577-88. PubMed ID: 20225066
[TBL] [Abstract][Full Text] [Related]
20. P38 MAP kinase signaling is required for the conversion of CD4+CD25- T cells into iTreg.
Huber S; Schrader J; Fritz G; Presser K; Schmitt S; Waisman A; Lüth S; Blessing M; Herkel J; Schramm C
PLoS One; 2008 Oct; 3(10):e3302. PubMed ID: 18827879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
